4//SEC Filing
OrbiMed Capital GP V LLC 4
Accession 0000947871-21-000249
CIK 0001626971other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:52 PM ET
Size
8.4 KB
Accession
0000947871-21-000249
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
Director10% Owner
Transactions
- Purchase
Common Stock, $0.0001 par value
2021-02-17$3.50/sh+1,285,714$4,499,999→ 8,053,298 total(indirect: See Footnotes)
OrbiMed Capital GP V LLC
Director10% Owner
Transactions
- Purchase
Common Stock, $0.0001 par value
2021-02-17$3.50/sh+1,285,714$4,499,999→ 8,053,298 total(indirect: See Footnotes)
Footnotes (3)
- [F1]These shares of the Issuer's common stock ("Shares") were purchased in a registered public offering.
- [F2]These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.
- [F3]This report is being jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter Thompson ("Thompson"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Thompson is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Corvus Pharmaceuticals, Inc.
CIK 0001626971
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001615374
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 4:52 PM ET
- Size
- 8.4 KB